The Guide is divided into 5 main parts:

  • (i) Drugs
  • (ii) Genes
  • (iii) Diseases
  • (iv) Appendix
  • (v) References

The section of Drugs includes 1,373 drugs classified in alphabetical order from A to Z. Each entry contains the following headings:

  • Drug Name
  • Brand Names [in 27 European countries (Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, UK), North America (Canada and USA), Latin America (Argentina, Brazil, Mexico), and Asia (Japan)]
  • Drug Combinations
  • Chemistry
  • Pharmacological Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions (cardiovascular, central nervous system, dermatologic, endocrine and metabolic, gastrointestinal, genitourinary, hematologic, hepatic, local, neuromuscular and skeletal, renal, respiratory, miscellaneous)
  • Pharmacogenetics (genotypes of risk, genes involved in drug metabolism, condition of substrate, inhibitor or inducer, when appropriate)
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics (absorption, distribution, protein binding, metabolism, bioavailability, half-life, time to peak, excretion)
  • Special Considerations (diet, age, sex, monitoring parameters).

The section of Genes includes 447 genes of relevance in pharmacogenomics. Each entry contains the following headings:

  • Gene Name
  • Alternative Names
  • Alternative Symbols
  • Locus
  • Codes (OMIM, PharmGKB)
  • Gene Structure
  • RNA
  • Protein
  • Function
  • Related Diseases (list of diseases investigated; in bold face those diseases potentially associated)
  • Related Drugs (list of drugs investigated; when appropriate, major substrates, minor substrates, strong inhibitors, moderate inhibitors, weak inhibitors, and inducers)
  • Animal Models
  • Allelic Variants
  • Selected SNPs
  • Evolution
  • Genomics and Pharmacogenomics (description of relevant findings in genomics and pharmacogenomics according to the international literature)
  • Drug-Gene Interactions.

The section of Diseases includes 4,471 drugs documented.

The Appendix includes 7 sub-sections:

  • (i) Pharmacogenomic synopsis (a list of internationally-used drugs with those genes potentially involved in the metabolism of each drug)
  • (ii) Genes-Diseases (a list of genes associated with specific diseases)
  • (iii) Diseases-Genes (a list of diseases associated with specific genes)
  • (iv) Classification of Drugs
  • (v) Classification of Diseases (ICD-10)
  • (vi) Receptors
  • (vii) Abbreviations

The section of References includes 2 categories: (i) Websites and International Databases, and (ii) 17,947 References alphabetically classified by author and by gene. The Guide’s authors have respected the data and opinions of the referenced original authors where contradictory results on drugs or genes are reported. Data included in the WGPGx have been strictly extracted from the referenced authors, avoiding personal interpretations. Approximately 100,000 references have been reviewed, of which 17,947 were finally selected for this edition.